Our laboratory integrates clinical, computational, and molecular biology expertise to determine the genomic drivers underlying initiation and progression of lymphoproliferative disorders. We aim to inform new strategies for early detection, prevention, and treatment of these diseases. Our laboratory is uniquely positioned within the Myeloma Service at the Department of Medicine at UM/SCCC, a world-leader in early drug development and cancer research, providing state-of-the art care for multiple myeloma patients across the United States and internationally. This ensures access to patient samples and clinical data derived from the use of cutting-edge therapies. Together with a strong network of collaborators, we are currently interrogating large datasets of whole genome, exome, RNA sequencing, and single-cell technologies to determine the impact of mutational signatures, structural variants, and rare drivers on multiple myeloma pathogenesis and clinical outcome.